Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
The company received one observation in the Form-483
The company is addressing these observations comprehensively
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Subscribe To Our Newsletter & Stay Updated
